The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

In one of the priciest health care deals of 2025, the pharmaceutical giant Merck has acquired the British drugmaker Verona Pharma, which has its U.S. headquarters in Raleigh, for roughly $10 billion.

THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen (AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking ...

We currently know that COPD, and specifically emphysema, don’t just happen alongside lung cancer; they increase a person’s ...

Join Rich Jones and Dr Mitchell Rothstein as they talk advances in COPD treatment. FREE lunch from Carrabba’s Italian Grill is included. Is chronic coughing or shortness of breath holding you back?

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...

Recent research suggests that certain biologic medications called monoclonal antibodies may help treat emphysema more effectively than some current therapies. These medications include benralizumab ...